Dissolution Enhancement of Poorly Soluble Drugs

Message from the Guest Editors

An increasing number of small molecules in the pipeline of pharmaceutical companies exhibit poor aqueous solubility, low dissolution rate, thus, poor bioavailability, which presents a major challenge in developing such molecules into medicines. To enhance the solubility and dissolution rate, several approaches have been developed, such as nano/micro-particle based formulations, amorphous solid dispersions, lipid-based drug delivery systems, pro-drugs, and co-crystals. Within the context of “Poorly Soluble Drugs,” this Special Issue aims to disseminate knowledge and information about novel materials, formulations, processes, characterization–testing methods, and provide a fundamental understanding of existing formulations–processes and insight into the mechanisms by which solubility/dissolution rate of the drugs are enhanced. Papers providing insight into the formation, structure, physico-chemical properties, and physical stability of the dosages with poorly water-soluble drugs as well as those exploring glass-forming ability of drugs, recrystallization tendency, and nano/microparticle formation are especially welcome.
Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High visibility:** indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews. Citations available in PubMed, full-text archived in PubMed Central. Covered by Scopus: papers published between 2014 and 2016 have been cited 3.68 times, on average, in 2017 (CiteScore 2017).

**Rapid publication:** manuscripts are peer-reviewed and a first decision provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 5.77 days (median values for papers published in the first six months of 2018).

Contact us

*Pharmaceutics*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
Fax: +41 61 302 89 18  
www.mdpi.com  
pharmaceutics@mdpi.com  
@MDPilpharma